Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 2Neurotoxicity Syndromes 1Neoplasm Metastasis 1Central Nervous System Carcinoma 1

Interventions

Radiotherapy 9Radiosurgery 6Oxaliplatin 5Cisplatin 5Paclitaxel 4Capecitabine 4Leucovorin 3Irinotecan 3Fluorouracil 3Doxorubicin 3Docetaxel 3strontium chloride 2regorafenib 2pembrolizumab 2enzalutamide 2Zoledronic Acid 2Temozolomide 2Radiofrequency Ablation 2Mitomycin 2Methods 2Ifosfamide 2Gemcitabine 2Filgrastim 2Educational Status 2Early Intervention, Educational 2Bleomycin 2Bevacizumab 2Analgesia 2Albumin-Bound Paclitaxel 2trifluridine tipiracil drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Neoplasm Metastasis × Memantine × Clear all
NCT00566852 2017-08-21

Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

Radiation Therapy Oncology Group

Phase 3 Completed
554 enrolled 12 charts
CNS

Brain Neoplasms, Neoplasm Metastasis, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡